The biotech landscape of 2026 is defined by a convergence of forces that are no longer theoretical but are actively reshaping how drugs are discovered, tested, and approved. From the FDA's formal ...

In 2026, biotechnology is experiencing a pivotal shift as landmark clinical results, regulatory reforms, and in vivo therapeutic platforms move from concept to practice. Breakthroughs such as the ...

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing ...